Your browser is no longer supported. Please, upgrade your browser.
Settings
INNT Innovate Biopharmaceuticals, Inc. daily Stock Chart
INNT [NASD]
Innovate Biopharmaceuticals, Inc.
Index- P/E- EPS (ttm)-3.91 Insider Own0.10% Shs Outstand24.03M Perf Week-24.19%
Market Cap56.47M Forward P/E- EPS next Y-0.97 Insider Trans- Shs Float12.94M Perf Month-19.80%
Income-24.60M PEG- EPS next Q-0.20 Inst Own11.40% Short Float5.67% Perf Quarter-61.97%
Sales0.60M P/S94.12 EPS this Y16.70% Inst Trans11.25% Short Ratio1.36 Perf Half Y-77.73%
Book/sh0.01 P/B235.00 EPS next Y- ROA-292.60% Target Price35.00 Perf Year-60.90%
Cash/sh0.34 P/C6.97 EPS next 5Y- ROE- 52W Range2.20 - 50.50 Perf YTD-61.48%
Dividend- P/FCF- EPS past 5Y- ROI1305.30% 52W High-95.46% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin15.00% 52W Low4.32% ATR0.43
Employees24 Current Ratio1.00 Sales Q/Q- Oper. Margin- RSI (14)36.08 Volatility19.40% 16.86%
OptionableYes Debt/Eq13.00 EPS Q/Q98.10% Profit Margin- Rel Volume0.58 Prev Close2.35
ShortableNo LT Debt/Eq0.00 Earnings- Payout- Avg Volume538.37K Price2.30
Recom2.00 SMA20-12.75% SMA50-38.57% SMA200-80.04% Volume311,685 Change-2.34%
Dec-17-18 08:00AM  Innovate Biopharmaceuticals Plans to Commence the First Ever Phase 3 Registration Trial in Celiac Disease in 1H 2019 and Announce Top-line NASH Data with Drug Combinations by EASL 2019 GlobeNewswire -16.96%
06:50AM  Today's Research Reports on Trending Tickers: Innovate Biopharmaceuticals and Tenet Healthcare ACCESSWIRE
Dec-14-18 02:45PM  Healthcare Stocks That Could Weather the Market Volatility ACCESSWIRE +8.43%
Dec-11-18 06:55AM  Today's Research Reports on Trending Tickers: Teva Pharmaceutical and Innovate Biopharmaceuticals ACCESSWIRE -7.74%
Dec-04-18 11:15AM  Innovate Biopharmaceuticals Enters into a Collaboration with Massachusetts General Hospital and Announces Capital Update for the Celiac Disease Clinical Program and its NASH Development Strategy on December 17, 2018 GlobeNewswire
Nov-26-18 06:00AM  Innovate Biopharmaceuticals Strengthens Clinical Development with the Addition of Patrick H. Griffin, M.D., F.A.C.P. GlobeNewswire
Nov-13-18 05:26PM  Innovate Biopharmaceuticals Reports Third Quarter 2018 Earnings and Key Corporate Highlights GlobeNewswire
Nov-12-18 08:10AM  Sanyal Biotechnology and Innovate Biopharmaceuticals Present Data at AASLD Validating a Proprietary Leaky Gut Assay Demonstrating Reduced Intestinal Permeability with Larazotide Acetate Treatment in a NASH Preclinical Study GlobeNewswire -9.11%
Nov-05-18 09:15AM  Innovate Biopharmaceuticals Announces Presentation at the BIO-Europe Conference, Copenhagen 2018 - 24th Annual Partnering Conference GlobeNewswire
Oct-31-18 09:00AM  Innovate Biopharmaceuticals Announces Participation at the Jefferies 2018 London Healthcare Conference GlobeNewswire
Oct-29-18 07:00AM  Innovate Biopharmaceuticals Announces Positive Effect of Larazotide Acetate on reducing Intestinal Permeability in a NASH Preclinical Study GlobeNewswire -11.01%
Oct-19-18 02:54PM  Innovate Biopharmaceuticals adds $5.2M to its coffers American City Business Journals
Oct-01-18 08:30AM  Innovate Biopharmaceuticals Announces Participation at the Ladenburg Thalmann 2018 Healthcare Conference GlobeNewswire
Sep-18-18 10:04AM  When Can We Expect A Profit From Innovate Biopharmaceuticals Inc (NASDAQ:INNT)? Simply Wall St.
Sep-06-18 07:30AM  Innovate Biopharmaceuticals to Host Clinical and Scientific Update Event on Thursday, September 6, 2018, in New York City. GlobeNewswire -15.10%
Sep-05-18 08:50AM  Is the Options Market Predicting a Spike in Innovate Biopharmaceuticals (INNT) Stock? Zacks -14.29%
Sep-04-18 08:00AM  Todays Research Reports on Stocks to Watch: Innovate Biopharmaceuticals and TapImmune ACCESSWIRE +25.84%
Aug-31-18 10:00PM  Innovate Biopharmaceuticals Announces Participation at the 20th Annual Rodman & Renshaw Global Investment Conference in New York City September 4-6, 2018 GlobeNewswire +36.14%
Aug-23-18 07:00AM  Innovate Biopharmaceuticals Enters into an Agreement with Amarex Clinical Research for Data Management and Biostatistics for Phase 3 Celiac Disease Trial GlobeNewswire
Aug-15-18 07:10AM  Innovate Biopharmaceuticals Reports Second Quarter 2018 Earnings and Key Corporate Highlights GlobeNewswire
Aug-03-18 07:05AM  Innovate Biopharmaceuticals to Host Clinical and Scientific Update Event on Thursday, September 6, 2018, in New York City GlobeNewswire
Jul-31-18 07:00AM  Innovate Biopharmaceuticals Enters into a Collaboration on Larazotides Effect on Improving the Microbiome of Children with EED with the University of Virginia School of Medicine GlobeNewswire
Jul-17-18 08:10AM  Todays Research Reports on Stocks to Watch: Genetic Technologies and Innovate Biopharmaceuticals ACCESSWIRE -8.17%
Jul-16-18 04:10PM  Why Innovate Biopharmaceuticals Stock Cratered Today Motley Fool -65.91%
Jun-28-18 07:00AM  Innovate Biopharmaceuticals Enters into an R&D Collaboration on Larazotides Corrective Effect on the Dysfunctional Intestinal Barrier and the Dysfunctional Microbiome in various Diseases with the University of Maryland School of Medicine GlobeNewswire
Jun-25-18 10:30AM  Innovate Biopharmaceuticals, Inc. added to membership of Russell 3000®, 2000® and the Russell Microcap® Indexes GlobeNewswire +39.48%
Jun-13-18 07:10PM  Innovate Biopharmaceuticals Announces Appointment of Saira Ramasastry to Board of Directors and Resignation of Anna Kazanchyan, M.D. GlobeNewswire
Jun-04-18 05:54PM  Is Innovate Biopharmaceuticals Incs (NASDAQ:INNT) Balance Sheet Strong Enough To Weather A Storm? Simply Wall St.
May-31-18 07:02AM  Innovate Biopharmaceuticals Scheduled to Present at the Jefferies Global Healthcare Conference in New York on Friday, June 8, 2018, at 11:30AM GlobeNewswire
May-22-18 08:01AM  Innovate Biopharmaceuticals Scheduled to Present at BIO 2018 Convention in Boston on Tuesday, June 5, 2018, at 4:45PM GlobeNewswire
May-17-18 03:06PM  Celiac Disease KOL and Management Meetings around the Digestive Disease Week (DDW) conference on Monday, June 4, 2018, in Washington, D.C. GlobeNewswire
May-16-18 09:10AM  Innovate Biopharmaceuticals Reports First Quarter 2018 Key Financial and Corporate Highlights GlobeNewswire +6.90%
May-09-18 02:07PM  Innovate Biopharmaceuticals Announces Acceptance of Two Abstracts for the Digestive Disease Week 2018 Conference GlobeNewswire -7.76%
Apr-10-18 06:31PM  Who Owns Innovate Biopharmaceuticals Inc (NASDAQ:INNT)? Simply Wall St.
Apr-05-18 06:03AM  Innovate Biopharmaceuticals, Inc. to Present at the H.C. Wainwright Annual Global Life Sciences Conference on April 9, 2018 GlobeNewswire
Mar-24-18 12:01AM  [$$] Charting the Market Barrons.com
Mar-13-18 07:32AM  Innovate Biopharmaceuticals appoints June Almenoff, M.D., Ph.D. as Chief Operating Officer and Chief Medical Officer GlobeNewswire -9.69%
Mar-07-18 07:32AM  Innovate Biopharmaceuticals to Highlight Progress in Celiac Disease and NASH at the Cowen Healthcare Conference on March 13, 2018, Tuesday at 8:40 AM ET GlobeNewswire -10.34%
Mar-06-18 08:20AM  Todays Research Reports on Stocks to Watch: Innovate Biopharmaceuticals and Clearside BioMedical ACCESSWIRE -16.18%
Feb-13-18 11:19AM  How Does Innovate Biopharmaceuticals Inc (NASDAQ:INNT)s Prospect Stack Up Next To Its Healthcare Peers? Simply Wall St.
Feb-07-18 10:30AM  Innovate Biopharmaceuticals to Highlight Progress in Celiac Disease and NASH at BIO CEO & Investor Conference on Monday, February 12, 2018 at 3:30PM ET GlobeNewswire -11.04%
Innovate Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases. The company's lead product candidate is INN-202 that has completed Phase 2b clinical trial for the treatment of celiac disease. It also develops INN-108, which has completed Phase 1 clinical trial to treat mild-to-moderate ulcerative colitis; INN-217 for the treatment of non-alcoholic steatohepatitis and microbiome; and INN-289 to treat crohn's disease. In addition, the company holds global rights for INN-329, a formulation of secretin that is used to enhance visualization in magnetic resonance cholangiopancreatography procedures that is in Phase 3 clinical trial. Innovate Biopharmaceuticals, Inc. is based in Raleigh, North Carolina.